1. Home
  2. IMAX vs MESO Comparison

IMAX vs MESO Comparison

Compare IMAX & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Imax Corporation

IMAX

Imax Corporation

HOLD

Current Price

$35.67

Market Cap

2.1B

Sector

N/A

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$16.72

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMAX
MESO
Founded
1967
2004
Country
Canada
Australia
Employees
N/A
81
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.1B
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
IMAX
MESO
Price
$35.67
$16.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
1
Target Price
$44.50
N/A
AVG Volume (30 Days)
991.7K
276.9K
Earning Date
04-30-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
31.25
N/A
EPS
0.63
N/A
Revenue
$410,212,000.00
N/A
Revenue This Year
$9.79
$629.74
Revenue Next Year
$7.51
$30.65
P/E Ratio
$55.48
N/A
Revenue Growth
16.47
N/A
52 Week Low
$22.50
$9.88
52 Week High
$43.16
$21.50

Technical Indicators

Market Signals
Indicator
IMAX
MESO
Relative Strength Index (RSI) 39.61 61.29
Support Level $33.34 $14.44
Resistance Level $37.52 $17.89
Average True Range (ATR) 1.44 0.53
MACD -0.30 0.29
Stochastic Oscillator 18.98 93.92

Price Performance

Historical Comparison
IMAX
MESO

About IMAX Imax Corporation

Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: